AR and neoplasm: However, recent data suggest that ER can act as a “rheostat” and that targeting AR biology in the context of high relative ER co-expression may require the use of AR agonists in the setting where AR acts as a tumor suppressor compared with low ER expression where targeting AR with inhibitors would be biologically supported.34